Livercellgram, bone marrow-derived mesenchymal stem cells for treatment of alcoholic liver cirrhosis

Livercellgram is product comprised of autologous bone marrow-derived mesenchymal stem cells (MSCs) and has been tested for treatment of alcoholic liver cirrhosis. The aim of a Phase III study was to elucidate the anti-fibrotic effect and to validate its safety of MSC treatment. Preliminary results have demonstrated histological improvement among 6 out of 11 patients receiving two treatment injections. In 10 patients, the Child-Pugh score improved, while levels of the liver fibrosis markers TGF-β1, collagen type-I and α-smooth muscle actin decreased significantly. No significant complications or side effects were observed during the study.